Developer docs
API playgroundTry for free, no card

Search company profiles

Recombinant Capital

Full company profile

uuid002s2w3

Namestring
Recombinant Capital
Legal namestring
Clarivate Plc
Websiteurl
recap.com
Company typeenum
Public
Founded yearint
1988
Descriptiontext

Clarivate Plc is a publicly traded (NYSE: CLVT) global intelligence company that provides proprietary data, analytics, workflow software, and expert services across three segments: Life Sciences & Healthcare, Intellectual Property, and Academia & Government. The company is headquartered in Philadelphia with regional offices in London, Barcelona, and Boston, and an operational footprint spanning the US, UK, Spain, China, Japan, and Korea. Its core Life Sciences portfolio centers on the Cortellis suite — Deals Intelligence (135k+ pharma deals, 15.5k+ with contracts, 9.6k unredacted), Competitive Intelligence, Clinical Trials Intelligence, Drug Discovery, Regulatory, and CMC modules — complemented by DRG disease/market intelligence and BioWorld news. The Intellectual Property portfolio is anchored by Derwent (Derwent World Patents Index covering 70m+ human-authored invention summaries across 60 patent authorities, plus Patent Search, Analytics, Monitor, Sequence Search, Chemistry Research, incoPat, Data Analyzer, and APIs) and CompuMark trademark solutions (SAEGIS, Brand Landscape Analyzer, Trademark Watch, plus Darts-ip case law). IP management software includes IPfolio, Inprotech, and FoundationIP. The Academia & Government segment comprises Web of Science, InCites, Journal Citation Reports, EndNote, ProQuest, and Ex Libris/Innovative library platforms (Alma, Primo, Leganto, Sierra).

The company's core technology is an AI-powered intelligence layer built atop proprietary, human-curated data assets. Notable components include purpose-built AI models trained by in-house staff (colBERT for patent search, LLM for patent classification), Cortellis Deals Predictive Analytics (trained on thousands of real-world pharma deals to forecast deal values and success probabilities by indication, phase, and deal type), and RiskMark — a 2025 product combining predictive and generative AI with 172.5m trademark records and 5m+ court decisions to produce risk scores and legally grounded draft arguments. Data feeds and APIs are used by 40+ national patent and trademark offices, indicating platform-level distribution beyond end-customer SaaS.

The business model is multi-stream: subscription SaaS for intelligence platforms (Cortellis, Derwent, CompuMark, Web of Science), professional services (270+ patent search professionals, IP recordals, annuities, docketing, translations), and enterprise data feeds/APIs for internal analytics integration. Pricing is quote-based and not publicly disclosed. Go-to-market is enterprise field sales targeting pharma/biotech business development and licensing teams, corporate IP and trademark departments, IP law firms, and academic/government institutions, supported by content marketing, webinars, podcasts, and industry events. Customer concentration is moderate, anchored by leading global pharma, top global brands (9 of 10 Interbrand 2025 best global brands use CompuMark), major IP law firms, and academic institutions, with recurring subscriptions providing revenue visibility. Note: the input data identifies the company as "Recombinant Capital" but contains no Recombinant Capital-specific facts; all substantive evidence pertains to Clarivate Plc.

Short descriptiontext

Clarivate Plc is a publicly traded global intelligence company providing AI-powered data, analytics, and expert services across life sciences, intellectual property, and academia for pharma, biotech, IP law firms, and academic institutions.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersSan Francisco, United States
HQ citystring
San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
biopharma deals intelligence, patent analytics software, trademark risk assessment, IP management platforms, research analytics software
Industry2 codes
PRIMARYBPAEAPAN
IP Management, Patents & Trademark Software
SECONDARYHDAAAHAC
Customer Churn, CLV & Retention Intelligence
NAICS code1 code
  • Software Publishers513210
SIC code1 code
  • Services-Prepackaged Software7372
Product category
Intellectual Property and Life Sciences Intelligence Software
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Subscription-based SaaS Access
TypeSubscription Recurring
Description

Annual subscription access to intelligence platforms including Cortellis Deals Intelligence, Derwent Patent Search, CompuMark trademark tools, and other analytics platforms. Provides continuous access to databases, analytics, and predictive tools with tiered pricing based on organization size and access level

clarivate.com
2Professional Services
TypeProfessional Services
Description

Expert consulting and services including patent search services (270+ search professionals), patent analytics services, IP management consulting, docketing, recordals, translations, and administrative support for IP workflows

clarivate.com
3Data Feeds and APIs
TypeData Monetisation
Description

Bulk data delivery via feeds or APIs for enterprise analytics, dashboards and applications powered by trusted biopharma deals intelligence and patent data

clarivate.com
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 11 records shown
1Cortellis
Description

Pharma deals intelligence and competitive intelligence platform providing comprehensive data on licensing, partnering, and M&A transactions

clarivate.com
+10 more records
Core offering1 text field

Recombinant Capital sells subscription-based AI-powered intelligence platforms and professional services across biopharma deals (Cortellis Deals Intelligence), patent research (Derwent), trademark clearance and watch (CompuMark, RiskMark), IP management software (IPfolio, Inprotech), academic research analytics (Web of Science, ProQuest), and library services (Ex Libris Alma, Primo). Revenue is generated primarily through annual subscriptions, data feeds/APIs, and expert services delivered to enterprise customers in life sciences, IP law, and academia.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Near-instant trademark conflict assessment replacing hours of manual research
+2 more records
Product overview1 text field

Clarivate is a multi-segment intelligence company offering a broad portfolio of data, analytics, workflow solutions, and expert services across three primary segments: Life Sciences & Healthcare (Cortellis, DRG, BioWorld), Intellectual Property (Derwent, CompuMark, Darts-ip, IP management software), and Academia & Government (Web of Science, ProQuest, Ex Libris/Innovative library platforms). The Life Sciences portfolio centers on Cortellis — a suite of pharma/biotech intelligence products spanning deals intelligence (Cortellis Deals Intelligence), competitive intelligence, drug discovery, clinical trials, regulatory intelligence, CMC intelligence, and product intelligence — complemented by DRG market assessment and epidemiology tools, and BioWorld biotech news. The IP portfolio is anchored by Derwent Patent Intelligence (including Derwent Patent Search, Derwent Patent Analytics, Derwent Patent Monitor, Derwent Sequence Search, Derwent Chemistry Research, Derwent World Patents Index, Derwent Data Analyzer, incoPat, and Derwent Patent Data APIs) and CompuMark trademark solutions (SAEGIS, Brand Landscape Analyzer, Trademark Watch Analyzer, RiskMark, TrademarkVision, DesignVision, Darts-ip). IP management software includes IPfolio, Inprotech, FoundationIP, and others. The Academia & Government segment includes Web of Science, InCites, Journal Citation Reports, Essential Science Indicators, EndNote, RefWorks, Pivot-RP, Esploro, Master Journal List, ProQuest platforms, and Ex Libris/Innovative library management systems (Alma, Primo, Leganto, Sierra, Polaris, Vega, Rapido, Rialto).

Product and service12 records
1Cortellis Deals Intelligence
CategoryBiopharma Deals Intelligence
Description

Biopharma deals intelligence platform providing comprehensive data and AI-powered analytics to evaluate, negotiate, and execute partnering, licensing, and M&A transactions. Covers 135k+ deals including early-stage deals, M&A, and 15.5k+ deals with contracts (9.6k unredacted). Includes first-in-class predictive deal value analytics for biotech and pharma BD&L teams.

2Derwent Patent Intelligence
CategoryPatent Search and Analytics
Description

Comprehensive patent search and analytics platform combining AI-powered tools with 70m+ human-authored Derwent invention summaries across 60 patent authorities. Used by corporate IP teams, patent attorneys, and patent offices for patentability, freedom-to-operate, invalidity, and portfolio analysis.

3CompuMark
CategoryTrademark Search and Brand Protection
Description

Comprehensive trademark intelligence suite covering the full trademark lifecycle — from screening and search (SAEGIS, Clearance Full Search, Brand Landscape Analyzer) to watching (Trademark Watch, Trademark Watch Analyzer), case law insights, and portfolio maintenance. Covers 168m+ trademark records, 500m+ global company names, and 187 trademark databases. Used by corporate trademark teams and brand-protection professionals.

4RiskMark
CategoryAI-Powered Trademark Risk Assessment
Description

AI-powered trademark risk assessment tool combining predictive and generative AI with CompuMark trademark data and Darts-ip global case law data to evaluate trademark conflicts based on precedent. Generates risk scores, legally grounded draft arguments, and case law insights across visual, phonetic, semantic, and goods/services similarity dimensions.

5Derwent Patent Data and APIs
CategoryPatent Data API / Feeds
Description

Patent data feeds and APIs providing direct, scalable access to high-quality, enriched global patent data for enterprise AI, workflow, and analytics platforms. Trusted by 40 global patent and trademark offices.

6Web of Science
CategoryAcademic Research Discovery and Citation Analytics
Description

Research discovery and citation indexing platform covering scholarly literature across sciences, social sciences, arts, and humanities with Web of Science Core Collection, APIs, and XML data for academic and government institutions.

7ProQuest
CategoryAcademic Content Platform
Description

Academic content platform providing essential content across disciplines and formats including ProQuest One Academic, ProQuest Dissertations & Theses, Ebook Central, ProQuest News & Newspapers, and Alexander Street academic video for libraries and academic institutions.

8Ex Libris Alma
CategoryLibrary Services Platform
Description

Cloud-based library services platform providing integrated library management for academic institutions with Ex Libris Open Platform for integrations.

9IPfolio
CategoryIP Management Software
Description

Cloud-based IP management platform for corporate IP teams providing portfolio management, workflow automation, and deadline tracking.

10Derwent Patent Search Services
CategoryProfessional IP Search Services
Description

Expert patent research services for high-confidence patentability, freedom to operate, and validity decisions delivered by 270+ search professionals.

11BioWorld
CategoryBiopharma News and Analysis
Description

Award-winning biotech and biopharma news platform providing actionable intelligence on the most innovative therapeutics and medical technologies in development.

12Cortellis Competitive Intelligence
CategoryPharma Competitive Intelligence
Description

Comprehensive pipeline and pharma competitive intelligence platform enabling critical portfolio decisions across the drug lifecycle.

Scale indicator14 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Operates Westlaw and other legal/regulatory intelligence products serving the same enterprise legal and corporate counsel buyers as Clarivate's IP and regulatory segments, with comparable enterprise SaaS economics and AI-augmentation roadmap.

TypeDirect peer
Description

Direct competitor in IP management software (Anaqua Platform, AQX) serving corporate IP teams and law firms — overlaps with Clarivate's IPfolio, Inprotech, and FoundationIP product lines.

TypeEmerging player
Description

AI-native patent analytics and intelligence platform competing with Derwent and incoPat — represents the emerging wave of faster-moving challengers applying LLMs and graph analytics to patent search.

TypeEmerging player
Description

Deals and private capital intelligence platform comparable to Cortellis Deals Intelligence for transaction data, valuation benchmarking, and M&A analytics — overlaps in customer use cases for dealmaking.

TypeDirect peer
Description

Direct competitor in life sciences intelligence: IQVIA's R&D and deal analytics overlap with Cortellis, DRG, and BioWorld for pharma BD&L, competitive intelligence, and clinical trial decision-making.

TypeBroad incumbent
Description

Provides expert information and software solutions across legal, regulatory, tax, and healthcare — directly comparable to Clarivate's IP, regulatory, and life sciences intelligence franchises with a similar vertical SaaS model and global enterprise footprint.

TypeBroad incumbent
Description

RELX's LexisNexis division is the closest broad incumbent peer: it competes head-on in legal and IP research (LexisNexis PatentSight, LexisNexis IP), shares a subscription SaaS model, and targets the same enterprise legal and corporate IP buyer. It is broader, with adjacent risk and scientific segments.

TypeBroad incumbent
Description

Comparable as a global data, analytics, and intelligence incumbent with subscription-based enterprise sales and adjacent exposure to financial, commodity, and industry intelligence — similar customer profile to Clarivate's enterprise accounts.

TypeEmerging player
Description

Patent and trademark intelligence specialist with PatBase and similar products, overlapping with Clarivate's Derwent and CompuMark franchises for IP and brand protection teams.

TypeRegional player
Description

Adjacent competitor in academic and library content/research intelligence, overlapping with Clarivate's Academia & Government segment (Web of Science, ProQuest) for institutional library and research customers.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat7 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
Yes

Docs URL, Description

Integration13 records

Each record includes

Title, Type, Description, Source

AI capability10 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Subsidiaries9 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance11 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Recombinant Capital

Intellectual Property and Life Sciences Intelligence Softwarerecap.com

Clarivate Plc is a publicly traded global intelligence company providing AI-powered data, analytics, and expert services across life sciences, intellectual property, and academia for pharma, biotech, IP law firms, and academic institutions.

What Recombinant Capital does

Clarivate Plc is a publicly traded (NYSE: CLVT) global intelligence company that provides proprietary data, analytics, workflow software, and expert services across three segments: Life Sciences & Healthcare, Intellectual Property, and Academia & Government. The company is headquartered in Philadelphia with regional offices in London, Barcelona, and Boston, and an operational footprint spanning the US, UK, Spain, China, Japan, and Korea. Its core Life Sciences portfolio centers on the Cortellis suite — Deals Intelligence (135k+ pharma deals, 15.5k+ with contracts, 9.6k unredacted), Competitive Intelligence, Clinical Trials Intelligence, Drug Discovery, Regulatory, and CMC modules — complemented by DRG disease/market intelligence and BioWorld news. The Intellectual Property portfolio is anchored by Derwent (Derwent World Patents Index covering 70m+ human-authored invention summaries across 60 patent authorities, plus Patent Search, Analytics, Monitor, Sequence Search, Chemistry Research, incoPat, Data Analyzer, and APIs) and CompuMark trademark solutions (SAEGIS, Brand Landscape Analyzer, Trademark Watch, plus Darts-ip case law). IP management software includes IPfolio, Inprotech, and FoundationIP. The Academia & Government segment comprises Web of Science, InCites, Journal Citation Reports, EndNote, ProQuest, and Ex Libris/Innovative library platforms (Alma, Primo, Leganto, Sierra).

The company's core technology is an AI-powered intelligence layer built atop proprietary, human-curated data assets. Notable components include purpose-built AI models trained by in-house staff (colBERT for patent search, LLM for patent classification), Cortellis Deals Predictive Analytics (trained on thousands of real-world pharma deals to forecast deal values and success probabilities by indication, phase, and deal type), and RiskMark — a 2025 product combining predictive and generative AI with 172.5m trademark records and 5m+ court decisions to produce risk scores and legally grounded draft arguments. Data feeds and APIs are used by 40+ national patent and trademark offices, indicating platform-level distribution beyond end-customer SaaS.

The business model is multi-stream: subscription SaaS for intelligence platforms (Cortellis, Derwent, CompuMark, Web of Science), professional services (270+ patent search professionals, IP recordals, annuities, docketing, translations), and enterprise data feeds/APIs for internal analytics integration. Pricing is quote-based and not publicly disclosed. Go-to-market is enterprise field sales targeting pharma/biotech business development and licensing teams, corporate IP and trademark departments, IP law firms, and academic/government institutions, supported by content marketing, webinars, podcasts, and industry events. Customer concentration is moderate, anchored by leading global pharma, top global brands (9 of 10 Interbrand 2025 best global brands use CompuMark), major IP law firms, and academic institutions, with recurring subscriptions providing revenue visibility. Note: the input data identifies the company as "Recombinant Capital" but contains no Recombinant Capital-specific facts; all substantive evidence pertains to Clarivate Plc.

Recombinant Capital firmographics

Firmographics
Name
Recombinant Capital
Legal name
Clarivate Plc
Website
https://recap.com
Company type
Public
Founded year
1988
Operating status
Operating
Headcount range
101–250 employees
Short description
Clarivate Plc is a publicly traded global intelligence company providing AI-powered data, analytics, and expert services across life sciences, intellectual property, and academia for pharma, biotech, IP law firms, and academic institutions.
Ownership category
akta.pro rank

Recombinant Capital industry classification

Industry
Product category
Intellectual Property and Life Sciences Intelligence Software
NAICS
Software Publishers (513210)
SIC
Services-Prepackaged Software (7372)
akta.pro industry
PRIMARYBPAEAPAN
IP Management, Patents & Trademark Software
SECONDARYHDAAAHAC
Customer Churn, CLV & Retention Intelligence

Keywords

  • Biopharma deals intelligence
  • Patent analytics software
  • Trademark risk assessment
  • IP management platforms
  • Research analytics software

Where Recombinant Capital is headquartered

Location

Headquarters

HQ city
San Francisco
HQ country
United States
HQ region
North America

Offices4 records

Markets served

Recombinant Capital business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Subscription-based SaaS Access: Annual subscription access to intelligence platforms including Cortellis Deals Intelligence, Derwent Patent Search, CompuMark trademark tools, and other analytics platforms. Provides continuous access to databases, analytics, and predictive tools with tiered pricing based on organization size and access level
  2. Professional Services: Expert consulting and services including patent search services (270+ search professionals), patent analytics services, IP management consulting, docketing, recordals, translations, and administrative support for IP workflows
  3. Data Feeds and APIs: Bulk data delivery via feeds or APIs for enterprise analytics, dashboards and applications powered by trusted biopharma deals intelligence and patent data

Go-to-market motion1 record

Distribution channels4 records

Marketing channels8 records

Recombinant Capital product offering

Product offering

Core offering

Recombinant Capital sells subscription-based AI-powered intelligence platforms and professional services across biopharma deals (Cortellis Deals Intelligence), patent research (Derwent), trademark clearance and watch (CompuMark, RiskMark), IP management software (IPfolio, Inprotech), academic research analytics (Web of Science, ProQuest), and library services (Ex Libris Alma, Primo). Revenue is generated primarily through annual subscriptions, data feeds/APIs, and expert services delivered to enterprise customers in life sciences, IP law, and academia.

Product overview

Clarivate is a multi-segment intelligence company offering a broad portfolio of data, analytics, workflow solutions, and expert services across three primary segments: Life Sciences & Healthcare (Cortellis, DRG, BioWorld), Intellectual Property (Derwent, CompuMark, Darts-ip, IP management software), and Academia & Government (Web of Science, ProQuest, Ex Libris/Innovative library platforms). The Life Sciences portfolio centers on Cortellis — a suite of pharma/biotech intelligence products spanning deals intelligence (Cortellis Deals Intelligence), competitive intelligence, drug discovery, clinical trials, regulatory intelligence, CMC intelligence, and product intelligence — complemented by DRG market assessment and epidemiology tools, and BioWorld biotech news. The IP portfolio is anchored by Derwent Patent Intelligence (including Derwent Patent Search, Derwent Patent Analytics, Derwent Patent Monitor, Derwent Sequence Search, Derwent Chemistry Research, Derwent World Patents Index, Derwent Data Analyzer, incoPat, and Derwent Patent Data APIs) and CompuMark trademark solutions (SAEGIS, Brand Landscape Analyzer, Trademark Watch Analyzer, RiskMark, TrademarkVision, DesignVision, Darts-ip). IP management software includes IPfolio, Inprotech, FoundationIP, and others. The Academia & Government segment includes Web of Science, InCites, Journal Citation Reports, Essential Science Indicators, EndNote, RefWorks, Pivot-RP, Esploro, Master Journal List, ProQuest platforms, and Ex Libris/Innovative library management systems (Alma, Primo, Leganto, Sierra, Polaris, Vega, Rapido, Rialto).

Differentiator

Problem solved

Functional benefit

Brands

  • Cortellis: Pharma deals intelligence and competitive intelligence platform providing comprehensive data on licensing, partnering, and M&A transactions
  • Derwent
  • CompuMark
  • BioWorld
  • Darts-ip
  • RiskMark
  • ProQuest
  • Ex Libris
  • Web of Science
  • EndNote
  • RefWorks

Products and services

  • Cortellis Deals Intelligence Biopharma deals intelligence platform providing comprehensive data and AI-powered analytics to evaluate, negotiate, and execute partnering, licensing, and M&A transactions. Covers 135k+ deals including early-stage deals, M&A, and 15.5k+ deals with contracts (9.6k unredacted). Includes first-in-class predictive deal value analytics for biotech and pharma BD&L teams.
  • Derwent Patent Intelligence Comprehensive patent search and analytics platform combining AI-powered tools with 70m+ human-authored Derwent invention summaries across 60 patent authorities. Used by corporate IP teams, patent attorneys, and patent offices for patentability, freedom-to-operate, invalidity, and portfolio analysis.
  • CompuMark Comprehensive trademark intelligence suite covering the full trademark lifecycle — from screening and search (SAEGIS, Clearance Full Search, Brand Landscape Analyzer) to watching (Trademark Watch, Trademark Watch Analyzer), case law insights, and portfolio maintenance. Covers 168m+ trademark records, 500m+ global company names, and 187 trademark databases. Used by corporate trademark teams and brand-protection professionals.
  • RiskMark AI-powered trademark risk assessment tool combining predictive and generative AI with CompuMark trademark data and Darts-ip global case law data to evaluate trademark conflicts based on precedent. Generates risk scores, legally grounded draft arguments, and case law insights across visual, phonetic, semantic, and goods/services similarity dimensions.
  • Derwent Patent Data and APIs Patent data feeds and APIs providing direct, scalable access to high-quality, enriched global patent data for enterprise AI, workflow, and analytics platforms. Trusted by 40 global patent and trademark offices.
  • Web of Science Research discovery and citation indexing platform covering scholarly literature across sciences, social sciences, arts, and humanities with Web of Science Core Collection, APIs, and XML data for academic and government institutions.
  • ProQuest Academic content platform providing essential content across disciplines and formats including ProQuest One Academic, ProQuest Dissertations & Theses, Ebook Central, ProQuest News & Newspapers, and Alexander Street academic video for libraries and academic institutions.
  • Ex Libris Alma Cloud-based library services platform providing integrated library management for academic institutions with Ex Libris Open Platform for integrations.
  • IPfolio Cloud-based IP management platform for corporate IP teams providing portfolio management, workflow automation, and deadline tracking.
  • Derwent Patent Search Services Expert patent research services for high-confidence patentability, freedom to operate, and validity decisions delivered by 270+ search professionals.
  • BioWorld Award-winning biotech and biopharma news platform providing actionable intelligence on the most innovative therapeutics and medical technologies in development.
  • Cortellis Competitive Intelligence Comprehensive pipeline and pharma competitive intelligence platform enabling critical portfolio decisions across the drug lifecycle.

Quantifiable outcome

  • Near-instant trademark conflict assessment replacing hours of manual research
  • +2 more outcomes

Companies that use Recombinant Capital

Customer profile

Named customers5 records

Segments4 records

Ideal customer profiles3 records

Recombinant Capital technology and API

Technology

Technology focussed Yes

API detail

Has API
Yes
API docs
API detail

Core technology

AI maturity

App detail

Integration13 records

AI capability10 records

Feature5 records

Recombinant Capital partnerships and signals

Strategic signal

Scale indicators14 records

Recent moves6 records

Expansion highlights4 records

Recombinant Capital competitors and assessment

Company assessment

Broad incumbents

  • Thomson Reuters: Operates Westlaw and other legal/regulatory intelligence products serving the same enterprise legal and corporate counsel buyers as Clarivate's IP and regulatory segments, with comparable enterprise SaaS economics and AI-augmentation roadmap.
  • Wolters Kluwer: Provides expert information and software solutions across legal, regulatory, tax, and healthcare — directly comparable to Clarivate's IP, regulatory, and life sciences intelligence franchises with a similar vertical SaaS model and global enterprise footprint.
  • LexisNexis (RELX): RELX's LexisNexis division is the closest broad incumbent peer: it competes head-on in legal and IP research (LexisNexis PatentSight, LexisNexis IP), shares a subscription SaaS model, and targets the same enterprise legal and corporate IP buyer. It is broader, with adjacent risk and scientific segments.
  • S&P Global (including IHS Markit): Comparable as a global data, analytics, and intelligence incumbent with subscription-based enterprise sales and adjacent exposure to financial, commodity, and industry intelligence — similar customer profile to Clarivate's enterprise accounts.

Direct peers

  • Anaqua: Direct competitor in IP management software (Anaqua Platform, AQX) serving corporate IP teams and law firms — overlaps with Clarivate's IPfolio, Inprotech, and FoundationIP product lines.
  • IQVIA: Direct competitor in life sciences intelligence: IQVIA's R&D and deal analytics overlap with Cortellis, DRG, and BioWorld for pharma BD&L, competitive intelligence, and clinical trial decision-making.

Emerging players

  • PatSnap: AI-native patent analytics and intelligence platform competing with Derwent and incoPat — represents the emerging wave of faster-moving challengers applying LLMs and graph analytics to patent search.
  • PitchBook (Morningstar): Deals and private capital intelligence platform comparable to Cortellis Deals Intelligence for transaction data, valuation benchmarking, and M&A analytics — overlaps in customer use cases for dealmaking.
  • Minesoft / PatInfo: Patent and trademark intelligence specialist with PatBase and similar products, overlapping with Clarivate's Derwent and CompuMark franchises for IP and brand protection teams.

Regional players

  • EBSCO Information Services: Adjacent competitor in academic and library content/research intelligence, overlapping with Clarivate's Academia & Government segment (Web of Science, ProQuest) for institutional library and research customers.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat7 records

Key risks6 records

Key highlights7 records

Customer concentration

Recombinant Capital social profiles

Digital presence

Recombinant Capital compliance and trust

Trust signal

Compliance11 records

Recombinant Capital financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Recombinant Capital leadership team

Management profile

Number of profiles

Recombinant Capital subsidiaries and ownership

Company hierarchy

Subsidiaries9 records

Recombinant Capital funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Recombinant Capital M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Recombinant Capital

What does Recombinant Capital do?

Recombinant Capital sells subscription-based AI-powered intelligence platforms and professional services across biopharma deals (Cortellis Deals Intelligence), patent research (Derwent), trademark clearance and watch (CompuMark, RiskMark), IP management software (IPfolio, Inprotech), academic research analytics (Web of Science, ProQuest), and library services (Ex Libris Alma, Primo). Revenue is generated primarily through annual subscriptions, data feeds/APIs, and expert services delivered to enterprise customers in life sciences, IP law, and academia.

Is Recombinant Capital a public or private company?

Recombinant Capital is a public company. It is classified as public and is currently operating.

When was Recombinant Capital founded?

Recombinant Capital was founded in 1988. It employs 101 to 250 people.

Where is Recombinant Capital based?

Recombinant Capital is headquartered in San Francisco, United States, in the North America region.

How does Recombinant Capital make money?

Three revenue lines are on record. Subscription-based SaaS Access are the primary driver. The others are professional Services and data Feeds and APIs.

Who are Recombinant Capital's main competitors?

Broad incumbents on record are Thomson Reuters, Wolters Kluwer, LexisNexis (RELX) and S&P Global (including IHS Markit). Direct peers are Anaqua and IQVIA. Emerging players are PatSnap, PitchBook (Morningstar) and Minesoft / PatInfo. EBSCO Information Services is listed as a regional player.

Does Recombinant Capital have an API?

Yes. Cortellis Deals Intelligence data can be delivered as bulk data via feeds or APIs to power internal analytics, dashboards, and enterprise applications with trusted biopharma deals intelligence.

What industry is Recombinant Capital in?

Recombinant Capital's product category is Intellectual Property and Life Sciences Intelligence Software. Its primary akta.pro industry code is BPAEAPAN, IP Management, Patents & Trademark Software, with a secondary code of HDAAAHAC, Customer Churn, CLV & Retention Intelligence. Its NAICS code is 513210 and its SIC code is 7372.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales